UPDATES IN MEDICINE

2021-07-10 17:09:04 ​​ RCT on inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac)

Nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group and 32 cases were reported in the placebo group 14 days or more after the second dose, yielding a vaccine efficacy of 83·5% (95% CI 65·4–92·1; p<0·0001). 

● Interpretation - CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile.


Join @Updates_in_Medicine
@The_Lancet Open / Comment

2021-07-09 05:02:40 Download our ANDROID APP

●https://play.google.com/store/apps/details?id=com.newandromo.dev607173.app768495 Open / Comment

2021-07-08 04:47:29 ​​ Effectiveness of SINOVAC Covid Vaccine

● Inactivated SARS-CoV-2 Vaccine in Chile

In a national prospective cohort study involving 10.2 million participants in Chile, the effectiveness of an inactivated SARS-CoV-2 vaccine, which had been developed in China and administered in two doses 28 days apart, was estimated. Effectiveness among fully immunized persons was estimated at 65.9% for Covid-19 and at 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-07-02 06:10:04 ​​ Transglutaminase 2 Inhibitor for Celiac Disease

In a phase 2 proof-of-concept trial, patients with celiac disease controlled on a gluten-free diet were assigned to one of three dose levels of ZED1227 (a selective transglutaminase 2 inhibitor) or placebo. Patients were challenged with 3 g of gluten daily for 6 weeks. Comparison of duodenal-biopsy samples between baseline and 6 weeks showed that ZED1227 attenuated gluten-induced mucosal damage. #gastroenterology


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-06-29 20:43:47 ​​ Another novel drug for diabetes
Another GLP 1 Analogue

● Cardiovascular and Renal Outcomes with Efpeglenatide

This trial compared weekly injections of efpeglenatide, an exendin-based glucagon-like peptide-1 receptor agonist, at a dose of 4 or 6 mg with placebo in participants with known type 2 diabetes and either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor. The risk of cardiovascular events was lower with efpeglenatide. #endocrinology #diabetes


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-06-28 04:23:41 ​​ Efficacy of novel Antidiabetic drug (dual GIP and GLP-1 receptor agonist) TRZEPATIDE in type 2 diabetes (SURPASS-1 trial)

● Interpretation - Tirzepatide showed robust improvements in glycaemic control and bodyweight, without increased risk of hypoglycaemia. The safety profile was consistent with GLP-1 receptor agonists, indicating a potential monotherapy use of tirzepatide for type 2 diabetes treatment.
#endocrinology #diabetes

Join @Updates_in_Medicine
@The_Lancet Open / Comment

2021-06-27 04:56:30 ​​ New Anti Diabetic Drug with Multiple Mechanisms of Action

● Tirzepatide versus Semaglutide for Type 2 Diabetes

This open-label, 40-week, phase 3 trial assessed the efficacy and safety of tirzepatide, a weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist under development for type 2 diabetes. Tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.



Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-06-26 05:03:29 ​​ 2021 American College of Rheumatology Guideline for the Management of Rheumatoid Arthritis



Join @Updates_in_Medicine Open / Comment

2021-06-25 20:12:57 What Is the Delta Plus Variant?
(Delta variant With K417N Mutation)

India said on Wednesday it has found around 40 cases of the Delta coronavirus variant carrying a mutation that appears to make it more transmissible.


Join @Updates_in_Medicine Open / Comment

2021-06-23 19:06:10 ​​ ADA New Living Standards of
Medical Care in Diabete

Three new changes to the American Diabetes Association's "living document" include recent trial data regarding cardiovascular and kidney disease in type 2 diabetes and type 1 diabetes prevention.


Join @Updates_in_Medicine Open / Comment